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Juvenile hyaline fibromatosis (JHF) is an autosomal recessive condition characterized by multiple subcutaneous
nodular tumors, gingival fibromatosis, flexion contractures of the joints, and an accumulation of hyaline in the
dermis. We performed a genomewide linkage search in two families with JHF from the same region of the Indian
state of Gujarat and identified a region of homozygosity on chromosome 4q21. Dense microsatellite analyses within
this interval in five families with JHF who were from diverse origins demonstrate that all are compatible with
linkage to chromosome 4q21 (multipoint LOD score 5.5). Meiotic recombinants place the gene for JHF within a
7-cM interval bounded by D4S2393 and D4S395.
Juvenile hyaline fibromatosis (JHF [MIM 228600]) is an
autosomal recessive condition that typically presents in
the first few years of life with skin lesions, often on the
scalp and ears, around the nose, and on the hands. These
lesions may be papular and/or nodular, and the distri-
bution and burden of lesions tends to increase through-
out childhood, often necessitating recurrent excision.
Gingival fibromatosis typically develops soon after the
skin lesions and may also require excision. Progressive
flexion contractures of joints increasingly limit move-
ment and may result in individuals becoming wheelchair
bound in early adulthood. Osteopenia is common; in-
telligence is normal. Diagnosis is confirmed by histolog-
ical examination of the skin, which typically shows an
abundance of a homogenous, amorphous, acidophilic
extracellular hyaline material, in which spindle-shaped
cells are embedded. The nature and origin of the hyaline
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material is unclear, but it appears to consist predomi-
nantly of collagens, glycosaminoglycans, and glycopro-
teins (Ishikawa et al. 1979; Mayer da Silva et al. 1988).
The condition has been termed “Murray syndrome,”
after the author of the original report (Murray 1873),
and “Puretic syndrome,” after the first author of a later
case report (Puretic et al. 1962). It has also been called
“juvenile systemic hyalinosis,” but the modern term was
introduced by Kitano et al. (1972). Predisposition to JHF
is likely to be an autosomal recessive trait, because there
is an equal sex distribution of cases; approximately one-
third of affected children are siblings, and many are born
to consanguineous parents. There is no apparent ethnic
predilection, with ∼40–50 cases from various popula-
tions reported in the literature (see Allen et al. 2001).
The underlying pathogenesis of JHF is unknown, and
no consistent biochemical abnormalities are present. It
has been postulated that JHF may be a disorder of col-
lagen metabolism, because abnormalities of collagen III
(Lubec et al. 1995; Breier et al. 1997) and collagen VI
(Kayashima et al. 1994) have been reported in some
patients. However, there are no consistent defects of col-
lagen, and many affected individuals have normal col-
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lagen profiles. Some investigators have suggested that
the abnormal collagen fibers result from an underlying
defect in glycosaminoglycan formation (Remberger et al.
1985). However, although abnormalities in the biosyn-
thesis of chondroitin sulphate and/or hyaluronic acid
have been reported in some patients (Kitano et al. 1972;
Iwata et al. 1980; Breier et al. 1997), they are not con-
sistently observed.
We ascertained two families with JHF that both orig-
inate from a small village in a remote area of the Gujarat
state of India (fig. 1). In family A, the proband (ID 7)
presented at age 2 years with multiple subcutaneous
swellings, initially on the scalp and later spreading to
the face, extremities, and trunk. By age 10 years, she
developed large nodules on the hands and feet that co-
incided with the underlying articular cartilage of the
knuckles and phalanges (fig. 2). These nodules require
surgical debulking at least twice a year. She has gingival
fibromatosis, and, since the age of 20 years, she has been
confined to a wheelchair because of progressive joint
contractures of the ankles, knees, and hips. A radiolog-
ical survey showed acro-osteolysis, and a skin biopsy
revealed excess hyaline deposition. She has two affected
distant relatives (ID 3 and ID 4), who have almost iden-
tical clinical histories, although their current mobility
status is unknown. In family B, a single person (ID 9)
is affected. He presented at age 2 years with skin nodules,
originally around the nose and ears and subsequently
on his fingers and toes. He also had severe gingival fi-
bromatosis that required frequent debulking but became
less prominent during his 20s. During childhood he de-
veloped progressive stiffness of the joints, predominantly
the knees, shoulders, and elbows. A radiological survey
showed generalized osteopenia, and his skin biopsy
showed excessive hyaline deposition.
There is no known relationship between these two
families, although both families are now living in Britain
and have relatively little knowledge of their distant rel-
atives. However, all ancestors of the affected children
originate from the same relatively isolated region of In-
dia, where they lived for several generations. Given the
rarity of JHF and the presumed autosomal recessive
transmission, we hypothesized that all the cases in these
two families were due to the same founder mutation and
that the patients would be homozygous for identical al-
leles in the vicinity of the JHF-predisposition locus.
We performed a genomewide linkage search in four
affected individuals, two unaffected siblings, and five par-
ents from the two families, after informed consent was
obtained. Four hundred microsatellite markers, spaced at
10-cM intervals, from ABI PRISM linkage-mapping set
version 2 (Applied Biosystems) were amplified by PCR,
using standard protocols. Amplified markers were elec-
trophoresed on an ABI 3770 DNA capillary sequencer
and were analyzed with GENESCAN and GENOTYPER
software (Applied Biosystems).
JHF was modeled as a fully penetrant autosomal re-
cessive trait, with a 0.01% population frequency of the
disease allele and with equal recombination fractions in
male and female individuals. Two-point LOD scores
were calculated using Fastlink (Cottingham et al. 1993),
and multipoint LOD scores were generated usingGENE-
HUNTER 2.1 (Kruglyak et al. 1996). Marker-allele fre-
quencies were estimated from unrelated individuals in
the five pedigrees with JHF.
In the original genome scan, only one marker,
D4S2964, was homozygous for the same allele in all
four affected individuals. At D4S392—the marker cen-
tromeric to D4S2964—two of the affected individuals
were homozygous for the same allele, and two affected
individuals were heterozygous. AtD4S1534, the marker
telomeric to D4S2964, three affected individuals were
homozygous for the same allele, and one individual was
heterozygous. This suggested that the gene for JHF was
between D4S392 and D4S1534 on chromosome 4q21.
To evaluate this further, an additional 12 microsatellite
markers from within the 17-cM interval flanked by
D4S392 and D4S1534 were analyzed. The order and
distance between these markers were obtained from
the Marshfield Genetic Database, and they are, in or-
der from centromeric to telomeric, D4S392 (1 cM),
D4S2389 (2.8 cM), D4S3042 (0 cM), D4S1558 (0.7
cM), D4S2915 (1.5 cM), D4S2393 (2 cM), D4S2963
(0 cM), D4S2947 (1 cM), D4S2964 (2 cM), D4S2922
(0 cM), D4S2932 (2 cM), D4S395 (1 cM), D4S1538 (1
cM), D4S2361 (2 cM), and D4S1534. The four affected
individuals from the two families were homozygous for
identical alleles at all five markers between D4S2393
and D4S395. None of the parents or unaffected siblings
were homozygous through this interval (fig. 1A and 1B).
To further evaluate the JHF locus on chromosome
4q21, we ascertained and analyzed three additional fam-
ilies with JHF (families C–E [fig. 1]). Family C originates
from Turkey and includes two affected sisters. Family D
is from Morocco and includes two affected brothers.
Both families are consanguineous. The clinical and his-
tological findings in families C and D are classical for
JHF and have been published elsewhere (Keser et al.
1999; Mancini et al. 1999). In family E, the proband
(ID 26) was born to unrelated European parents and
presented with erythematous-squamous lesions of the
knuckles at age 1 mo (Rimbaud et al. 1974). At age 15
mo, a perianal tumor was removed. At age 18 mo, dif-
fuse painful swelling of the joints and limitation ofmove-
ments of large and small joints were noted. At 2 years
of age, severe gingival fibromatosis was noted, together
with nodules and papules around the lips, nose, scalp,
and ears. Histologic examination of the skin lesions re-
vealed fibrohyaline deposits, and a skeletal survey re-
Figure 1 Haplotypes for 13 markers from chromosome 4q21 in five families with JHF. Blackened symbols indicate individuals affected with
JHF. In families A–D, boxes around marker alleles indicate the region of homozygosity. In family E, all vertical bars next to the alleles indicate the
segregating haplotypes and show that the parental chromosome 4q21 haplotypes inherited by the affected individual (ID 26) are different from
those of his unaffected siblings. Critical meiotic recombinants in ID 11, ID 22, and ID 23 refine the minimal interval encompassing the JHF-
predisposition gene to the region between D4S2393 and D4S395.
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Table 1
Combined Two-Point LOD Scores at Chromosome
4q21 Markers in Five Families with JHF
Marker
Two-Point LOD Score at v p
.00 .05 .1 .2 .3 .4
D4S2389 1.32 1.28 1.11 .72 .39 .15
D4S3042 2.28 1.87 1.60 1.12 .67 .30
D4S1558 1.76 1.40 1.19 .84 .52 .24
D4S2915 .94 .71 .57 .38 .24 .11
D4S2393 .90 1.11 1.04 .74 .44 .19
D4S2963 2.10 1.66 1.26 .64 .26 .07
D4S2947 2.34 1.92 1.54 .93 .52 .23
D4S2964 2.80 2.35 1.93 1.23 .71 .32
D4S2922 3.06 2.63 2.23 1.51 .91 .41
D4S2932 1.58 1.31 1.07 .68 .38 .16
D4S395 4.22 3.61 3.02 1.97 1.12 .47
D4S1538 3.90 3.33 2.79 1.81 1.02 .42
D4S2361 1.20 1.26 1.10 .70 .37 .13
Figure 2 Hands of ID 7, showing nodular lesions and subcutaneous swellings that are typical of JHF
vealed osteolytic lesions in the metaphyses. At age 20
years, the patient was still alive, but he had severe joint
limitation.
Families C–E were analyzed with 13 microsatellite
markers from the chromosome 4q21 interval that was
defined in the original two families. In family C, the
affected individual (ID 14) was homozygous at all 13
markers, whereas her unaffected sister was heterozygous
through this interval. The marker alleles differed from
those segregating in the two Gujarati families. This sug-
gests that a separate Turkish founder mutation in the
JHF gene is acting in family C. In family D, both affected
boys are genotypically identical through the JHF region
and are homozygous at all markers between D4S2393
and D4S2681. Again, the alleles at these markers differ
from those seen in both the Gujarati families and the
Turkish family, suggesting that a separate mutation is
responsible for the disease in these brothers from Mo-
rocco. In family E, the affected boy has inherited chro-
mosome 4 haplotypes that are different from those of
both of his unaffected siblings, consistentwithmutations
in the JHF gene on chromosome 4q21 acting in this
family. The parents are not related, and the affected child
has inherited different marker alleles from each parent
and is thus likely to be a compound heterozygote for
two separate mutations in the chromosome 4q21 JHF-
predisposition gene, although it is possible that a dif-
ferent JHF-predisposition gene is acting in this family.
The maximum two-point LOD score for all the families
combined is 4.22 at D4S395 (table 1). The maximum
multipoint LOD score for all five families is 5.5 (fig. 3).
In families B and D, critical meiotic recombinants that
delimit the regions of homozygosity in these two fam-
ilies place the JHF-predisposition gene in a 7-cM region
bounded by D4S2393 and D4S395.
Our data provide strong evidence for the location of
a recessive JHF-predisposition gene on chromosome
4q21. The genomic sequence of the critical interval is
incomplete, but scrutiny of the Project Ensembl and the
University of California, Santa Cruz, Human Genome
Project Working Draft databases indicates that the min-
imal interval is ∼6 Mb and contains 19 known genes
and 47 predicted genes. Several of the known genes are
of potential interest as candidates, including bone mor-
phogenetic protein 3 (BMP3), fibroblast growth factor
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Figure 3 Combined multipoint LOD score at chromosome 4q21 in five families with JHF
5 (FGF5), protein kinase cGMP-dependent, type II
(PRKG2), and the human homologue of mouse BMP-
2–inducible kinase (BIKE).
Several conditions show some overlap with JHF, and
they should now be examined for linkage to chromo-
some 4q21. Foremost among these is infantile systemic
hyalinosis (ISH [MIM 236490]). This is an autosomal
recessive condition that is also histologically character-
ized by hyaline deposits in the dermis. ISH has been
primarily discriminated from JHF by its severe clinical
course. Onset is in the first few months, typically with
painful joint contractures and hyperpigmentation over
bony prominences. Affected children develop early pap-
ules (predominantly on the face, scalp, and neck), fleshy
nodules (particularly in the perianal region), and nodular
plaques (particularly over the proximal interphalangeal
joints of the hands). Gingival fibromatosis and osteo-
penia are often present. Affected children may have a
protein-losing enteropathy and are susceptible to infec-
tions, and they usually die of overwhelming sepsis and/
or multiorgan failure within the first few years of life.
Autopsy reveals widespread hyaline deposition in many
tissues, including skin, skeletal muscle, cardiac muscle,
gastrointestinal tract, lymph nodes, spleen, thyroid, and
adrenal glands (Landing et al. 1986; Glover et al. 1991,
1992; Sahn et al. 1994; Stucki et al. 2001).
Winchester syndrome (MIM 277950) also shows con-
siderable overlap with JHF and ISH. This condition pre-
sents in early childhood and is characterized by short
stature, coarse facial features, joint contractures, gingi-
val fibromatosis, osteoporosis, and peripheral corneal
opacities (Dunger et al. 1987; Prapanoch et al. 1992).
Other conditions that share some features with JHF
include congenital generalized fibromatosis (MIM
228550), the stiff skin syndrome (MIM 184900), lipoid
proteinosis (MIM 247100), pseudo-Hurler polydystro-
phy (MIM 252600), Farber disease (MIM 228000), and
I-cell disease (MIM 252500). However, these conditions
should be distinguishable from JHF by clinical, genetic,
biochemical, and/or histological findings.
It has been suggested that JHF may not be as rare as
is generally assumed and that milder cases may be mis-
diagnosed because the histological appearances are not
well known (Allen 2001). It is hoped that identification
of the underlying predisposition gene will lead to de-
velopment of a molecular diagnostic test and to better
information about the incidence and phenotypic spec-
trum of the disorder. Advancement in our knowledge of
the pathogenesis of JHF will allow insights to be gained
into the fundamental defect in the condition and may
also increase our understanding of the likely pathways
and mechanisms that are subverted in conditions with
related phenotypes.
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